June 3, 2019

Rivaroxaban Reduces VTE in Patients with Pancreatic Cancer

Add prophylaxis for patients receiving systemic therapy

650x450_Khorana_ASCO-pancreatic-cancer

Rivaroxaban is an effective thromboprophylactic for patients with pancreatic cancer receiving systemic therapy, according to a subanalysis of the CASSINI trial presented at the American Society of Clinical Oncology’s 2019 annual meeting.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The multicenter, risk-adapted CASSINI trial demonstrated that rivaroxaban significantly reduces venous thromboembolism (VTE) and VTE-related deaths for outpatient, at-risk cancer patients during the intervention period. Alok Khorana, MD, Vice Chair of Clinical Services and Director of the Gastrointestinal Malignancies Program, was co-chair of the steering committee of the trial and presented the results as a late-breaking abstract at the 2018 American Society of Hematology meeting. The results were also published in the New England Journal of Medicine in February 2019.

The current study sought to establish rivaroxaban’s efficacy in ambulatory patients with pancreatic cancer, who are at particular risk of VTE. “Patients with pancreatic cancer have among the highest risk of VTE observed in any solid tumor,” says Dr. Khorana.

A change in practice is warranted

CASSINI included 841 patients, of which 273 (32.6%) had pancreatic cancer; median age of this subgroup was 66 years, and 57% were male. Patients at high risk for VTE (Khorana score ≥ 2) were randomized one-to-one to rivaroxaban 10 mg once daily or a placebo for 180 days. Patients received a screening ultrasound as well as a blood draw every eight weeks starting at baseline.

Advertisement

Only 2.75% of patients with pancreatic cancer who took rivaroxaban developed blood clots (symptomatic deep vein thrombosis, asymptomatic proximal DVT, pulmonary embolism and VTE-related death) compared with 10.1% of the placebo group (HR 0.35; 95% CI, 0.13- 0.97; P = 0.03) during intervention. The rate of International Society on Thrombosis and Hemostasis-defined major bleeding, the primary safety endpoint, did not increase and occurred in 1.5% of patients in the treatment arm and 2.3% in the placebo arm.

When adding secondary endpoints (arterial/visceral events) to primary, benefit from rivaroxaban increased further, with only 4% of patients experiencing events on rivaroxaban versus 12% in the placebo arm (HR, 0.34; 95% CI, 0.14-0.87, P = 0.02).

“This study provides further evidence for what we hope becomes a change in practice in our approaches to preventing cancer-associated VTE,” says Dr. Khorana. “For pancreatic cancer patients, prevention of these events is even more important given the known high rate of thrombosis and lack of increased bleeding observed in our analysis.”

Advertisement

Related Articles

22-CNR-IV-Drip-CQD-Hero-650×450-1
April 20, 2022
Combination Chemo-Immunotherapy Appears to Improve Outcomes in Muscle-Invasive Bladder Cancer

New results from the BLASST-1 trial show increases in downstaging and relapse-free survival

Mammary carcinoma with lobular features. Breast cancer
April 12, 2022
MRI May Be Best Tool for Tumor Staging and Detecting Bilateral Disease in Invasive Lobular Carcinoma

Study highlights value of preoperative imaging to guide surgical decision-making

rt-breast_650x450
July 1, 2021
Designing an Optimal Breast Cancer Radiation Protocol

How a novel tissue marker makes a difference

PrimaryPulmonaryCarcinoid
June 29, 2021
Achieving Cost-Effectiveness with Adjuvant Osimertinib for NSCLC

Model identifies target OS at which economic benefits of treatment outpace placebo

650×450-Prostate-Cancer
June 25, 2021
Upfront Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Setting a new benchmark for control arm estimates

650×450-bladder
May 24, 2021
Combination Maintenance Therapy in Metastatic Urothelial Cancer

In search of improved outcomes for patients

Ad